Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stimcell EnergeticsSTME 23 Cash-to-Debt is 0.00 as of May. 2026. GuruFocus rates STME with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Stimcell Energetics ranks worse than 118764.73% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Stimcell Energetics's cash to debt ratio for the quarter that ended in May. 2026 was 0.00.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Stimcell Energeticscouldn't pay off its debt using the cash in hand for the quarter that ended in May. 2026.
The historical rank and industry rank for Stimcell Energetics's Cash-to-Debt or its related term are showing as below:
During the past 13 years, Stimcell Energetics's highest Cash to Debt Ratio was 0.14. The lowest was 0.00. And the median was 0.08.
STME's Cash-to-Debt is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.635 * Ranked among companies with meaningful Cash-to-Debt only.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Stimcell Energetics Cash-to-Debt Related Terms
Stimcell Energetics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Stimcell Energetics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, Stimcell Energetics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stimcell Energetics Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stimcell Energetics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Stimcell Energetics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stimcell Energetics (STME) has a Cash-to-Debt of 0.00 as of May. 2026. According to the industry distribution chart, Stimcell Energetics ranks #999999 out of 842 companies in the Medical Devices & Instruments industry.
Is Stimcell Energetics' Cash-to-Debt too high?
Stimcell Energetics' current Cash-to-Debt is 0.00. Based on the distribution chart, Stimcell Energetics ranks #999999 out of 842 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Stimcell Energetics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Stimcell Energetics' Cash-to-Debt compare to AMIX and ITOC?
According to the Medical Devices & Instruments industry distribution chart, Stimcell Energetics ranks #999999 out of 842 companies for Cash-to-Debt. This places Stimcell Energetics in the lower half of its industry. The industry median Cash-to-Debt is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stimcell Energetics's current Cash-to-Debt is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stimcell Energetics stock overvalued right now?
Stimcell Energetics (STME) has a current Cash-to-Debt of 0.00. The current Cash-to-Debt is 0.00. Stimcell Energetics' overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Stimcell Energetics (STME), the current Cash-to-Debt is 0.00 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Stimcell Energetics Inc is a biotech company focused on the discovery, development, and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness, and alleviate health complications, including, but not limited to: aging, diabetes, high blood pressure, neuropathy, and kidney function. The company's main focus is on continued research and development of its eBalance Technology and its eBalance Home System.
23GF Score
Get the complete analysis for STME
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STME has been successfully added to your 
